BRPI1008920A2 - Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho - Google Patents

Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho

Info

Publication number
BRPI1008920A2
BRPI1008920A2 BRPI1008920-9A BRPI1008920A BRPI1008920A2 BR PI1008920 A2 BRPI1008920 A2 BR PI1008920A2 BR PI1008920 A BRPI1008920 A BR PI1008920A BR PI1008920 A2 BRPI1008920 A2 BR PI1008920A2
Authority
BR
Brazil
Prior art keywords
rtki
eye
release
pharmaceutical composition
tyrosine kinase
Prior art date
Application number
BRPI1008920-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Bhagwati P Kabra
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI1008920A2 publication Critical patent/BRPI1008920A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1008920-9A 2009-03-03 2010-03-03 Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho BRPI1008920A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15698409P 2009-03-03 2009-03-03
PCT/US2010/025998 WO2010101971A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Publications (1)

Publication Number Publication Date
BRPI1008920A2 true BRPI1008920A2 (pt) 2015-08-25

Family

ID=42678477

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008920-9A BRPI1008920A2 (pt) 2009-03-03 2010-03-03 Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho

Country Status (11)

Country Link
US (1) US20100226992A1 (cg-RX-API-DMAC10.html)
EP (1) EP2403342A4 (cg-RX-API-DMAC10.html)
JP (1) JP5583145B2 (cg-RX-API-DMAC10.html)
KR (1) KR20110123789A (cg-RX-API-DMAC10.html)
CN (2) CN105362221A (cg-RX-API-DMAC10.html)
AU (1) AU2010221438C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1008920A2 (cg-RX-API-DMAC10.html)
CA (1) CA2753837A1 (cg-RX-API-DMAC10.html)
MX (1) MX2011008680A (cg-RX-API-DMAC10.html)
WO (1) WO2010101971A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201105506B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
BR112014014342A2 (pt) * 2011-12-14 2017-06-13 Abbvie Inc composições contendo inibidores de cinase
WO2013138393A1 (en) * 2012-03-12 2013-09-19 Allergan, Inc. Method of treating ophthalmic conditions with kinase inhibitors
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
HK1220632A1 (zh) 2013-09-20 2017-05-12 参天制药株式会社 含有聚乙二醇的组合物
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
AU2015317531B2 (en) * 2014-09-17 2020-11-19 Panoptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
EP3302061A4 (en) * 2015-06-05 2019-02-27 Kato Pharmaceuticals, Inc. UREA COMPOSITIONS WITH EXTENDED RELEASE
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
WO2021051003A1 (en) 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
JP7653164B2 (ja) * 2019-09-27 2025-03-28 バージニア コモンウェルス ユニバーシティー 組織を修復または増加させるための組成物および方法
CN116251186B (zh) * 2021-12-09 2025-04-25 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3931319A (en) * 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5300287A (en) * 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5624962A (en) * 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation
EP0842663A4 (en) * 1996-05-07 2003-06-18 Toray Industries OPHTHALMIC PREPARATIONS
BR9806123A (pt) * 1997-07-29 1999-08-31 Alcon Lab Inc Soluções condicionantes para cuidado de lente de contato dura
BR0013793A (pt) * 1999-09-06 2002-05-14 Ono Pharmaceutical Co Medicamentos profiláticos e terapêuticos para doenças oftálmicas
DE60006262T2 (de) * 1999-09-24 2004-05-13 Alcon, Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
WO2001039765A2 (en) * 1999-12-03 2001-06-07 Ista Pharmaceuticals, Inc. Compositions and methods for the induction and treatment of retinal detachments
WO2001087262A2 (en) * 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Stabilized steroidal suspension
AU2001277891A1 (en) * 2000-07-26 2002-02-05 Alcon Universal Ltd. Pharmaceutical suspension compositions lacking a polymeric suspending agent
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
US20030139382A1 (en) * 2001-09-21 2003-07-24 Alcon, Inc. Method of treating middle ear infections
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
KR100976076B1 (ko) * 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
DK1755616T3 (da) * 2004-04-08 2013-11-25 Eye Co Pty Ltd Behandling af ekssudativ retinopati med mineralkortikoider
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
SI1885336T1 (sl) * 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
AU2006244245B2 (en) * 2005-05-10 2010-11-18 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
CA2693888A1 (en) * 2007-07-20 2009-01-29 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension

Also Published As

Publication number Publication date
EP2403342A1 (en) 2012-01-11
AU2010221438A1 (en) 2011-08-25
AU2010221438B2 (en) 2014-10-16
JP2012519692A (ja) 2012-08-30
AU2010221438C1 (en) 2015-01-29
WO2010101971A1 (en) 2010-09-10
CN105362221A (zh) 2016-03-02
US20100226992A1 (en) 2010-09-09
CN102340993A (zh) 2012-02-01
MX2011008680A (es) 2011-09-08
KR20110123789A (ko) 2011-11-15
ZA201105506B (en) 2012-09-26
EP2403342A4 (en) 2013-06-05
CA2753837A1 (en) 2010-09-10
JP5583145B2 (ja) 2014-09-03

Similar Documents

Publication Publication Date Title
BRPI1012302A2 (pt) composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho
ZA201105506B (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
HRP20161312T1 (hr) Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
EP2376495A4 (en) COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
BRPI0911988A2 (pt) micelas para liberação intracelular de agentes terapêuticos.
PT2435030E (pt) Composições farmacêuticas flutuantes de libertação controlada
BR112012004525A2 (pt) composição farmacêuticas gástrico-rententivas para liberação imediata ou prolongada de acetaminofeno
BRPI0913235A2 (pt) forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona
PT2214646T (pt) Dendrímeros para libertação sustentada de compostos
EP2694060A4 (en) SUBSTITUTED 3- (1H-BENZO- {D} -IMIDAZOL-2-YL-) 1H-INDAZOL ANALOGUE AS PDK1 KINASE INHIBITOR
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
EP2142287A4 (en) INHIBITORS OF LYSINPECIFIC DEMETHYLASE
UY33094A (es) Procedimiento para la preparacion de dronedarona
BRPI0812250A2 (pt) Composição farmacêutica de liberação lenta feita de micropartículas
EP2515657A4 (en) Tyrosine kinase inhibitor
EP2930167A4 (en) TINOSOLINE INHIBITOR USED AS COMPLETE INDOLKETONE DERIVATIVE
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
BRPI0909270A2 (pt) Compostos de sirna para inibição de rtp801
EP2231152A4 (en) THIENOPYRANONE AS A KINASEHEMMER
TN2009000510A1 (en) Extended release formulation of nevirapine
BRPI0923003A2 (pt) composição de liberação controlada para produção de uma preparação de liberação prolongada contendo udenafil
HRP20150752T1 (xx) Piridinil- i pirazinilmetoksiarilni derivati, korisni kao inhibitori slezenske tirozinske kinaze

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]